Wei Ding

6.1k total citations
117 papers, 2.2k citations indexed

About

Wei Ding is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Wei Ding has authored 117 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Genetics, 59 papers in Pathology and Forensic Medicine and 34 papers in Immunology. Recurrent topics in Wei Ding's work include Chronic Lymphocytic Leukemia Research (100 papers), Lymphoma Diagnosis and Treatment (57 papers) and Immunodeficiency and Autoimmune Disorders (28 papers). Wei Ding is often cited by papers focused on Chronic Lymphocytic Leukemia Research (100 papers), Lymphoma Diagnosis and Treatment (57 papers) and Immunodeficiency and Autoimmune Disorders (28 papers). Wei Ding collaborates with scholars based in United States, China and Australia. Wei Ding's co-authors include Neil E. Kay, Timothy G. Call, Tait D. Shanafelt, Susan M. Schwager, Sameer A. Parikh, Susan L. Slager, José F. Leis, Kari G. Rabe, Diane F. Jelinek and Clive S. Zent and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Wei Ding

109 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wei Ding United States 25 1.7k 1.2k 751 479 411 117 2.2k
Osnat Bairey Israel 27 1.2k 0.7× 1.4k 1.2× 486 0.6× 338 0.7× 598 1.5× 103 2.5k
Jacqueline C. Barrientos United States 27 2.3k 1.3× 1.9k 1.6× 995 1.3× 672 1.4× 630 1.5× 178 2.9k
Stephen Opat Australia 25 1.4k 0.8× 1.7k 1.5× 562 0.7× 570 1.2× 980 2.4× 158 2.7k
Carolyn Owen Canada 21 2.1k 1.2× 1.8k 1.5× 782 1.0× 989 2.1× 702 1.7× 99 3.1k
Paolo Strati United States 29 1.1k 0.7× 906 0.8× 632 0.8× 764 1.6× 961 2.3× 141 2.5k
Francesca Romana Mauro Italy 31 2.4k 1.4× 1.7k 1.4× 1.3k 1.8× 739 1.5× 630 1.5× 157 3.3k
Barbara Grant United States 17 1.6k 1.0× 1.6k 1.4× 456 0.6× 337 0.7× 512 1.2× 32 2.4k
Deborah M. Stephens United States 22 1.0k 0.6× 1.1k 0.9× 342 0.5× 354 0.7× 630 1.5× 142 1.7k
Charles Herbaux France 23 1.1k 0.6× 1.2k 1.0× 591 0.8× 460 1.0× 675 1.6× 111 1.9k
Christian H. Geisler Denmark 25 1.2k 0.7× 1.8k 1.5× 512 0.7× 305 0.6× 1.1k 2.7× 52 2.4k

Countries citing papers authored by Wei Ding

Since Specialization
Citations

This map shows the geographic impact of Wei Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Ding more than expected).

Fields of papers citing papers by Wei Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Ding. The network helps show where Wei Ding may publish in the future.

Co-authorship network of co-authors of Wei Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Wei Ding. A scholar is included among the top collaborators of Wei Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei Ding. Wei Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Soumerai, Jacob D., Chan Y. Cheah, Mary Ann Anderson, et al.. (2024). Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101. Blood. 144(Supplement 1). 1012–1012. 7 indexed citations
3.
Huntington, Scott F., Stephen J. Schuster, Wei Ding, et al.. (2023). DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal of Hematology. 98(5). 739–749. 7 indexed citations
4.
Iyer, Prajish, Lu Yang, Sutapa Sinha, et al.. (2023). Beyond CLL Progression: Unveiling Th17 and Th2 T Cell Subsets As Predictors of Pembrolizumab Response in Richter's Transformation. Blood. 142(Supplement 1). 1888–1888.
5.
Tsang, Mazie, Paul J. Hampel, Kari G. Rabe, et al.. (2023). A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 41(16_suppl). 12057–12057.
6.
Zhao, Fang, Jennifer L. Oliveira, Yuan Ji, et al.. (2022). Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer Journal. 12(2). 30–30. 6 indexed citations
7.
Ravindran, Aishwarya, Paul J. Kurtin, Rebecca L. King, et al.. (2022). Aberrant expression of lymphoid enhancer–binding factor 1 in Hodgkin lymphoma. Human Pathology. 125. 2–10. 2 indexed citations
8.
Kay, Neil E., Sameer A. Parikh, Kari G. Rabe, et al.. (2022). Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma. 64(2). 300–311. 2 indexed citations
9.
Parikh, Sameer A., Kari G. Rabe, Neil E. Kay, et al.. (2021). The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 138(2). 149–159. 23 indexed citations
10.
Ding, Wei. (2021). The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America. 35(4). 739–759. 1 indexed citations
11.
Hou, Jing-Zhou, Jing Christine Ye, Jeffrey J. Pu, et al.. (2021). Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. Journal of Hematology & Oncology. 14(1). 66–66. 41 indexed citations
12.
Tian, Shulan, Henan Zhang, Pan Zhang, et al.. (2021). Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. Scientific Reports. 11(1). 8318–8318. 3 indexed citations
13.
Whitaker, Jennifer A., Sameer A. Parikh, Tait D. Shanafelt, et al.. (2021). The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine. 39(7). 1122–1130. 25 indexed citations
14.
Parikh, Sameer A., Sara J. Achenbach, Timothy G. Call, et al.. (2020). The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Medicine. 9(10). 3390–3399. 39 indexed citations
15.
Hampel, Paul J., Timothy G. Call, Wei Ding, et al.. (2020). Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Advances. 4(18). 4508–4511. 13 indexed citations
16.
Damlaj, Moussab, Nanna Sulai, Jennifer L. Oliveira, et al.. (2015). Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. Clinical Lymphoma Myeloma & Leukemia. 15(11). 699–704. 9 indexed citations
17.
Fiorcari, Stefania, Wells S. Brown, Bradley W. McIntyre, et al.. (2013). The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells. PLoS ONE. 8(12). e83830–e83830. 75 indexed citations
18.
Min, Rui, et al.. (2012). Research of the Soft Decision Decoding Algorithm Based on Belief Propagation. 1 indexed citations
19.
Shah, Dipesh K., Lyle D. Joyce, Martha Grogan, et al.. (2011). Recurrent Pulmonary Intimal Sarcoma Involving the Right Ventricular Outflow Tract. The Annals of Thoracic Surgery. 91(3). e41–e42. 14 indexed citations
20.
Zent, Clive S., Wei Ding, Megan S. Reinalda, et al.. (2009). Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leukemia & lymphoma. 50(8). 1261–1268. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Osnat Bairey Breakdown of academic impact, for papers by Jacqueline C. Barrientos Breakdown of academic impact, for papers by Stephen Opat Breakdown of academic impact, for papers by Carolyn Owen Breakdown of academic impact, for papers by Paolo Strati Breakdown of academic impact, for papers by Francesca Romana Mauro Breakdown of academic impact, for papers by Barbara Grant Breakdown of academic impact, for papers by Deborah M. Stephens Breakdown of academic impact, for papers by Charles Herbaux Breakdown of academic impact, for papers by Christian H. Geisler
Rankless by CCL
2026